White House Flips Out Over Report Trump May Be on Weight Loss Drug
A stunning report reveals the president may have gotten an early access to an obesity drug to treat major medical issues.

A White House spokesperson flipped out Tuesday after he was quoted failing to deny a report suggesting President Donald Trump may have been given early access to a weight loss drug.
A STAT report Tuesday found that one 79-year-old man had received special access to retatrutide, a powerful new weight loss drug—prompting speculation that the individual in question was none other than the president of the United States.
White House spokesperson Kush Desai publicly lashed out at STAT’s Lizzy Lawrence, who in her original report, noted that Desai did not explicitly deny that Trump was the patient in question.
“Because this has to be spelled out for @LizzyLaw_, who has proven herself to be an unserious gossip columnist, this application was not for the President,” Desai wrote on X Tuesday after the story quickly gained national attention.
“Thank you for clarifying. I asked you, the FDA, and HHS multiple times yesterday whether this application was for the President. No one answered my question directly,” Lawrence replied.
“We shouldn’t have to bat down baseless speculation for you to not print it. Any reporter with standards would understand this,” Desai wrote. “Are you going to now go ask this idiotic question to the ~4 million Americans in this age cohort and then speculate about them being the application?”
As a White House spokesperson, it’s Desai’s responsibility to respond to queries from the press. As TNR contributor Nina Burleigh pointed out on X: “If you don’t want to do your job, maybe stop taking taxpayer funds…”
Desai did little to dismiss the story when it first came across his desk and originally referred STAT to the Department of Health and Human Services, which didn’t offer a denial either.
In fact, Desai may have fueled further questions about the president’s health. When the 79-year-old patient requested “compassionate use” access to retatrutide in April, it was to treat refractory obesity with obstructive sleep apnea and pulmonary hypertension.
Asked whether Trump has obstructive sleep apnea and pulmonary hypertension, Desai originally told STAT a White House memo on Trump’s most recent medical evaluation “covers this.” It does not.



